mitochondrial ribosomal protein S22Genealiases: C3orf5 · COXPD5 · GIBT · GK002 · MRP-S22 · ODG7
Q-omics provides the consensus-scored MRPS22 profile across patient tissues and cancer cell-line models. MRPS22 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MRPS22 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MRPS22 protein abundance shows 22,388 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, THCA, and LSCC as cancer lineages where MRPS22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS22 survival associations across molecular data types. MRPS22 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS22 RNA expression–survival associations across cancer types. High MRPS22 expression shows unfavorable associations in KICH, PAAD, ACC, HNSC, SCLC and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MRPS22 RNA expression.
This table summarizes MRPS22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS22 shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, BLCA, LUSC and STAD. The THCA box plot shows higher MRPS22 RNA expression in normal versus tumor tissue (log2 FC = −0.733, t-test p < 0.001).
This table shows molecular features associated with MRPS22 in patient tissues and cancer cell lines. In patient samples, MRPS22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
